We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Elan Corporation, plc (ELN)
An SI Board Since October 1996
Posts SubjectMarks Bans Symbol
10345 174 0 ELN
Emcee:  Harold Engstrom Type:  Moderated
Elan is a bio/pharmaceutical company with roots in Ireland and the US. It has 2 primary foci: biologic and small molecule treatments for neurologic indications and drug delivery.

They currently have several sources of revenue:
* Drug delivery manufacturing and R&D contract services
* Nanotechnology drug delivery licensing and manufacturing services (among major drugs approved are Tricor (5%), and Magace, and Palperidone Palmitate (Invega approved Aug 2009), and fampridine (18% royalty) approved Jan 2010)
* Tysabri - a monoclonal antibody product approved by the FDA and EMEA for MS and in US for Crohn's Disease
* Prialt, an intrathecally delivered synthetic toxin for relieving pain otherwise untreatable by morphine (EU marketing/sales rights sold to Eisai 2/2006)

In R&D are:
* AAB-001 mAb for Alzheimer's Disease (P3) (50% Pfizer, 25.5% JNJ, 24.5% Elan)
* ACC-001 immunoconjugate for Alzheimer's Disease (P2) (50% Pfizer, 25.5% JNJ, 24.5% Elan)
* gamma secretase program for Alzheimer's Disease (pre-clinical, promising)
* right to 50% of Eli Lilly's gamma secretase AD program (P3)
* ELND-001: anti-VLA4 small molecules for RA (P1)
* ELND-002: anti-VLA4 small molecules for MS (P2)
* ELND-005/AZD-103: beta amyloid oral prophylactic (roll to P3 expected by YE2010) (70% Elan, 30% TTHI)
* ELND-006: molecule that inhibit cleavage of misfolded APP by gamma secretase
* PD - various pre-clinical candidates (IND 2010?)
* EDT: mix of hard-to-value products in various stages of development

This thread is now moderated: please be civil and keep the discussion on topic (about Elan.) Shorts and Longs are both welcome with the caveat that cheerleading and slamming without reasoning and sources to back them up are not welcome.
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
10345Royalty Pharma Announces Proposal To Acquire Elan Message 28744728sim1-2/25/2013
10344Not enough for BIIB to buy the whole company. What's left for ELAN?Qualified Opinion-2/6/2013 justice.govQualified Opinion111/22/2012
10342What's left for ELAN? Elan Corporation PLC ( ELN) Will Shuttesteve kammerer110/1/2012
10341George Soros bullish on Elan. [graphic]Slugger15/20/2012
103404-16-2012 chart and setup for ELN here is my chart and setup for this week for Mark3000-4/14/2012
10339WSJ <i> Novartis Gilenya Patient Gets Rare Brain Disease By tom pope-4/13/2012
10338Good news today: The U.S. Food and Drug Administration allowed marketing of theArthur Radley21/20/2012
10337From this week's Nature issue: Call for Proposals Grants for research on Biotech Jim-12/2/2011
10336Deciding she should take T was not that hard for me. Getting her to do it was mIRWIN JAMES FRANKEL211/24/2011
10335So glad to hear good news. Improvement is wonderful. I recognize it must have pgo-neil-11/23/2011
10334Congrats to her and you! JonRobohogs-11/23/2011
10333Karen has now been on T for about 44 months now. Since the post that I am replyIRWIN JAMES FRANKEL911/23/2011
10332Data about Early Use and Long-Term Benefit of TYSABRI Presented at 5th Joint Trisim1110/19/2011 Is this why ELN has been going up as of late? Teva Pharmaceutsteve kammerer-8/1/2011
10330European Commission Approves Inclusion of Anti-JC Virus Antibody Status as a PMLsim116/22/2011
10329UBS upgraded Elan Corp (ELN, $10.22, +$0.56, +5.80%) (ELN.DB) to buy from neutrasjemmeri26/9/2011
10328So should one buy ALKS in advance of this. Is there anything left in the alzeimsteve kammerer-5/9/2011
10327Alkermes to Merge with Elan Drug Technologies to Create Alkermes plc — Creates sim1-5/9/2011
10326Alkermes to Merge With Irish Drug Business By CHRIS V. NICHOLSON [NYT] May 9, sim1-5/9/2011
10325biib doing better than elnhdl-4/21/2011
10324Tysabri 1Q11 in-market sales: $170M US, $180M ex-US, $349M total:
10323bloomberg.comArthur Radley-4/15/2011 Radley13/29/2011
10321Thanks for sharing--only dined there once, but he was a great host. Before we leArthur Radley-3/25/2011
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):